Tango Therapeutics (TNGX) Enterprise Value (2020 - 2025)
Tango Therapeutics (TNGX) has 6 years of Enterprise Value data on record, last reported at -$343.1 million in Q4 2025.
- For Q4 2025, Enterprise Value fell 33.04% year-over-year to -$343.1 million; the TTM value through Dec 2025 reached -$343.1 million, down 33.04%, while the annual FY2025 figure was -$343.1 million, 33.04% down from the prior year.
- Enterprise Value reached -$343.1 million in Q4 2025 per TNGX's latest filing, down from -$94.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$428000.0 in Q2 2025 and bottomed at -$506.1 million in Q3 2021.
- Average Enterprise Value over 5 years is -$250.4 million, with a median of -$307.7 million recorded in 2024.
- Peak YoY movement for Enterprise Value: tumbled 212683.58% in 2021, then skyrocketed 99.87% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$487.5 million in 2021, then grew by 24.9% to -$366.1 million in 2022, then skyrocketed by 81.62% to -$67.3 million in 2023, then crashed by 283.32% to -$257.9 million in 2024, then crashed by 33.04% to -$343.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$343.1 million in Q4 2025, -$94.5 million in Q3 2025, and -$428000.0 in Q2 2025.